Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of DS-1211b in pseudoxanthoma elasticum
NL-OMON51483Phase 2Completed
- Sponsor
- Daiichi Sankyo, Inc
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DL-404 in pseudoxanthoma elasticum (PXE) (4 arms), sponsored by Daiichi Sankyo, Inc. Primary endpoints: Safety and tolerability and Dose response in pharmacodynamic endpoints. Started Mar 2022; status: completed.
02
Drugs
DL-404
03
Conditions
pseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on NL-OMON51483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51483.